← Oncology Approval Tracker

FDA DECISION ·

Ponlimsi

denosumab-adet · Teva Pharmaceuticals

Biosimilar approvalBiosimilarTreatment-associated bone loss
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Prolia biosimilar with oncology supportive-care uses to increase bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitors for breast cancer.

LAMPGEN ANALYSIS

Why it matters

The labeled uses address bone loss associated with cancer treatment. This product and its uses should be kept distinct from the Xgeva-referenced formulation.

What research teams should watch

Verify the underlying cancer therapy and fracture risk, and align product selection with renal and calcium safety monitoring described in the label.

PRIMARY RECORDS

Sources